Article Sidebar
Published:
Jun 12, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Investigation of the potential pharmacological mechanism of action of Danhong injection against chronic heart failure using a network pharmacol ogy based approach
Abstract
Purpose: To investigate the mechanism of action of Danhong Injection (DHI) in chronic heart failure (CHF).
Methods: Network pharmacology was employed to identify the bioactive compounds and targets of DHI in CHF. Bioinformatics analysis was used to examine the potential biological functions and pathways of the candidate targets, while molecular docking was conducted to evaluate the binding affinity of the ligand-protein complex.
Results: Based on data mining from public databases, 65 bioactive ingredients and 246 potential targets of DHI were identified, along with 786 CHF-related genes. There were 48 common targets between DHI targets and CHF-related genes, and a protein-protein interaction (PPI) network of common targets containing 42 nodes and 204 edges was constructed. The 48 common targets were considered as effector proteins exerting anti-CHF effects, and they were shown to be involved in multiple signal-transduction pathways and disease-related pathways by bioinformatics analysis. Most of these targets had protein-binding capability and were located in plasma membrane as well as extracellular regions. The biological process of these proteins was primarily associated with gene regulation, response to hypoxia, and heart development. Binding capability between these active ingredients and proteins was further validated by molecular docking simulation.
Conclusion: This study has shed new light on the pharmacological mechanism of action of DHI’s effects on CHF, thus offering fresh leads for additional research into DHI's potential to cure CHF.
